Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.49 |
| ▸ | MGLL | Q99685 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515890 | 0.88 | LMNA (0.55) | FAAHMGLLLMNAALDH1A1TSHR | |
| SCHEMBL514945 | 0.86 | LMNA (0.61) | FAAHMGLLLMNAALDH1A1TSHR | |
| SCHEMBL3117003 | 0.84 | LMNA (0.65) | FAAHMGLLLMNAALDH1A1TSHR | |
| SCHEMBL515320 | 0.84 | LMNA (0.65) | FAAHMGLLLMNAALDH1A1TSHR | |
| SCHEMBL8430088 | 0.84 | LMNA (0.65) | FAAHMGLLLMNAALDH1A1TSHR | |
| SCHEMBL3112597 | 0.84 | LMNA (0.65) | FAAHMGLLLMNAALDH1A1TSHR | |
| SCHEMBL515404 | 0.84 | LMNA (0.65) | FAAHMGLLLMNAALDH1A1TSHR | |
| SCHEMBL3122706 | 0.84 | LMNA (0.65) | FAAHMGLLLMNAALDH1A1TSHR | |
| SCHEMBL14473886 | 0.83 | FAAH (0.47) | FAAHMGLLLMNAALDH1A1TSHR | |
| SCHEMBL12793746 | 0.82 | FAAH (0.46) | FAAHMGLLLMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798059-A | Preparation method of 3-ethylbicyclo [3.2.0] hept-3-en-6-one | 江西同和药业股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119798059-A | Preparation method of 3-ethylbicyclo [3.2.0] hept-3-en-6-one | 江西同和药业股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-109942474-B | O-azido-hydrazine compound and preparation method thereof | 华中科技大学 | 2020-09-18 | — | — | CN | disclosed |
| CN-102369173-B | Method for producing high-purity terminal olefin compound | KURARAY CO | 2014-09-10 | — | — | CN | disclosed |
| EP-2415740-B1 | METHOD FOR PRODUCING HIGH-PURITY TERMINAL OLEFIN COMPOUND | KURARAY CO (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8609886-B2 | Method for producing high purity terminal olefin compound | KURARAY CO., LTD. (JP) | 2013-12-17 | — | — | US | disclosed |
| CN-102369173-A | Method for producing high-purity terminal olefin compound | KURARAY CO | 2012-03-07 | — | — | CN | disclosed |
| EP-2415740-A1 | METHOD FOR PRODUCING HIGH-PURITY TERMINAL OLEFIN COMPOUND | Kuraray Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029229-A1 | METHOD FOR PRODUCING HIGH PURITY TERMINAL OLEFIN COMPOUND | KURARAY CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| CN-101035753-A | (4E) Process for producing (E) -5-chloro-2-isopropyl-4-pentenoate and optically active substance thereof | ASAHI GLASS CO LTD (JP) | 2007-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029229-A1 | METHOD FOR PRODUCING HIGH PURITY TERMINAL OLEFIN COMPOUND | ADH1A, ADH1C, OSBP | FAAH 136/4885MGLL 960/4885LMNA 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.